TrialDiabetes care2022

Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.

Evangelos K Oikonomou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.